Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

IDP-118 · Bryhali, Duobrii

Small molecule · Modulator of glucocorticoid receptor (NR3C1) and retinoic acid receptor alpha (RARA) · developed by Bausch

Approved FDA, Apr 2019

BHC Developer

1 Registered trials

What is IDP-118?

IDP-118 (Duobrii) is a topical combination of halobetasol propionate, a corticosteroid, and tazarotene, a retinoid. The precise mechanism in psoriasis is unknown, though corticosteroids affect cellular signaling, immune function, and inflammation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Bryhali, Duobrii, Halobetasol Propionate, Ultravate
Drug type: Small molecule
Targets: glucocorticoid receptor (NR3C1), retinoic acid receptor alpha (RARA)
Mechanism: Modulator of glucocorticoid receptor (NR3C1) and retinoic acid receptor alpha (RARA)
Pathways: immune_function, inflammation, cellular_signaling
Therapy area: Dermatology
Developer: Bausch (BHC)
FDA status: Approved as Bryhali, Duobrii, Halobetasol Propionate (April 25, 2019), NDA209354 · FDA label

✅ FDA-approved uses

Plaque psoriasis (Duobrii)

From the indications section of the FDA label (version of Jan 1, 2020). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03988439	Phase 4	Psoriasis	Completed	BHC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Psoriasis

Other drugs acting on NR3C1 / RARA

Beclomethasone Dipropionate FDA approved Budesonide FDA approved Halobetasol Propionate And Tazarotene FDA approved Infacort FDA approved Methylprednisolone FDA approved Mifepristone FDA approved Mometasone FDA approved Mometasone Furoate FDA approved Relacorilant FDA approved Chronocort Phase 3 Exicorilant Phase 1/2 Miricorilant Phase 2

More from Bausch

Adapalene / Benzoyl Peroxide / Clindamycin FDA approved Brodalumab FDA approved Bupropion FDA approved Halobetasol Propionate And Tazarotene FDA approved IDP-126 FDA approved Lifitegrast FDA approved Perfluorohexyloctane FDA approved Plecanatide FDA approved Rifaximin FDA approved Timolol FDA approved BL1107 Phase 2 BL1332 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BHC page.

Follow BHC, the company behind IDP-118

See BHC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BHC catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z